Novavax reports results of Phase I Ebola GP Vaccine trial

Clinical-stage vaccine firm Novavax has presented positive top-line data from a Phase I clinical trial of its Ebola virus glycoprotein (GP)recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M (TM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news